Latest news about Vasundhara Rasayans
Vasundhara Rasayans
154.00
-0.45(-0.29%)
Company Performance:
View Company Insights1D-0.29%
1M-11.49%
6M+18.14%
1Y-16.08%
5Y+22.71%
More news about Vasundhara Rasayans
30Mar 26
Vasundhara Rasayans Ltd Receives Lease Extension for Manufacturing Facility Till April 30, 2026
Vasundhara Rasayans Ltd has secured a one-month lease extension for its Maharashtra manufacturing facility, with the termination date moved from March 31, 2026 to April 30, 2026. The extension from lessor Keva Fragrances Private Limited provides additional time for the company to identify alternative premises and ensure business continuity. This follows the original termination notice disclosed on December 29, 2025.
10Feb 26
Vasundhara Rasayans Reports 50.4% Decline in Q3FY26 Net Profit to ₹72.05 Lakhs
Vasundhara Rasayans Ltd reported challenging Q3FY26 results with net profit declining 50.4% to ₹72.05 lakhs from ₹145.28 lakhs in Q3FY25. Revenue from operations fell 15.6% to ₹744.77 lakhs, while total expenses decreased to ₹714.39 lakhs. For nine months FY26, net profit dropped 13.1% to ₹335.05 lakhs with revenue declining 9.2% to ₹2,382.99 lakhs. EPS for the quarter stood at ₹2.27 compared to ₹4.57 in the previous year.
06Sept 25
Vasundhara Rasayans Declares Rs. 2 Per Share Dividend, Appoints New Directors
Vasundhara Rasayans Limited has announced a dividend of Rs. 2.00 per equity share. The company appointed Shri Ashok Kumar Jain as Additional Independent Director and Shri Kodakandla Sidarsanam as additional Whole-time Director. The 37th Annual General Meeting (AGM) is scheduled with book closure from September 24-30 and a cut-off date of September 23 for e-voting and dividend eligibility. Mrs. Rakhi Agarwal has been appointed as the e-voting Scrutinizer for the AGM.
13Aug 25
Vasundhara Rasayans Reports Q1 Net Profit of ₹57.28 Crore, Down 33.5% Year-on-Year
Vasundhara Rasayans Limited announced Q1 financial results, showing a 2.08% increase in total income to ₹824.50 lakh, but a 33.51% decrease in net profit to ₹57.28 lakh. Net sales slightly decreased by 0.90% to ₹756.15 lakh. Total expenses rose by 8.08% to ₹747.10 lakh, primarily due to increased finance costs and other expenses. Earnings per share dropped from ₹2.71 to ₹1.80. The company operates in the agri products segment.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Dr Reddys Laboratories
Laurus Labs
Aurobindo Pharma
1,902.40
(-0.08%)
8,597.00
(+0.32%)
4,896.50
(-2.17%)
1,432.20
(-0.40%)
1,120.00
(+1.11%)
2,201.80
(+0.01%)
2,384.00
(-0.04%)
1,174.70
(-0.45%)
1,802.00
(-1.26%)
1,621.30
(+0.83%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
